The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biomarkers market size reached US$ 56.78 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 124.05 Billion by 2027, exhibiting a growth rate (CAGR) of 12.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Biomarkers, also known as biological markers, are molecules or genes that are used as indicators of the health or status of an organ, tissue, or cell. In addition to blood and bodily fluids, biomarkers are also found in tissues. In the discovery and development of new drugs, biomarkers are used for risk assessment, molecular diagnostics, disease diagnosis, DNA fingerprinting, and eliminating complexity. As a result, they play a crucial role in improving the drug development process, drug validation and testing, sample preparation and assay development. Biomarkers are often integrated with key imaging technologies that can provide clear images of oncology tumors and other problems while also eliminating the possibility of radiation exposure during CT scans and MRI scans.
The market is majorly driven by the rising incidences of numerous chronic diseases among the masses, particularly in the geriatric population. In addition to this, the increasing implementation of biomarkers in infectious disease diagnosis is propelling the market. Moreover, continual developments in biomarker-based diagnostics, such as biomarker signatures resulting in faster drug development, non-invasive testing, and early diagnosis, are also creating a positive market outlook. In line with this, the rapid utilization of biomarkers in the development of companion diagnostics to identify drug target molecules is providing an impetus to the market. Also, the escalating demand for personalized medicine, along with a paradigm shift toward biomarker studies from conventional pathophysiology and epidemiology methods, is fueling the market. Furthermore, a considerable rise in the number of contract research organizations facilitating cost-efficient clinical trials are creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities and the increasing medical expenditure.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarkers market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, type, disease, application and end user.
Breakup by Product:
Breakup by Type:
Breakup by Disease:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Type, Disease, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at